15/04/2025 08:17
EQS-News: Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Annual Report/Annual Results br/ Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year... Lire...
03/03/2025 14:38
EQS-News: Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Personnel br/ Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG br/br/ 03.03.2025 / 14:38... Lire...
13/02/2025 14:10
EQS-News: First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Conference br/ FirstInHuman Data about the Treatment of MuscleInvasive Bladder Cancer with Pentixapharm’s Lu177PentixaTher to be Presented... Lire...
24/01/2025 17:00
EQS-Adhoc: Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Pentixapharm Holding AG / Key words: Preliminary Resultsbr/ Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7... Lire...
07/01/2025 10:30
EQS-News: Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Agreement br/ Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope br/br/ 07.01.2025 / 10:30... Lire...
21/11/2024 13:41
Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
html xmlns=http://www.w3.org/1999/xhtmlbodytable border=trtd p OriginalResearch: Pentixapharm Holding AG von BankM AG br/br/ 21.11.2024 / 13:40 CET/CESTbr/ Veröffentlichung einer Research, übermittelt durch EQS News ein Service der EQS Group AG.br/ Für den Inhalt der... Lire...
21/11/2024 11:00
EQS-News: First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Study br/ First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177PentixaTher, Expanding the... Lire...
12/11/2024 17:45
EQS-News: Pentixapharm Releases Interim Report for the Third Quarter of 2024
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Quarterly / Interim Statement br/ Pentixapharm Releases Interim Report for the Third Quarter of 2024 br/br/ 12.11.2024 / 17:45... Lire...
04/11/2024 17:26
EQS-News: Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Statement br/ Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals br/br/ 04.11.2024 /... Lire...